Epstein-Barr Virus–Associated Posttransplantation Lymphoproliferative Disorder Following Lung Transplantation Is More Commonly of Host Origin

2006 ◽  
Vol 130 (2) ◽  
pp. 176-180 ◽  
Author(s):  
Michael R. Peterson ◽  
Shawn C. Emery ◽  
Gordon L. Yung ◽  
Eliezer Masliah ◽  
Eunhee S. Yi
Keyword(s):  
Polymerase Chain Reaction ◽  
Lung Transplantation ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Chain Reaction ◽  
Barr Virus ◽  
Host Origin ◽  
Polymerase Chain ◽  
Epstein Barr ◽  
Posttransplantation Lymphoproliferative Disorder

Abstract Context.—Posttransplantation lymphoproliferative disorder (PTLD) in patients who have undergone solid organ transplantation is thought to be mostly of host (ie, transplant recipient) origin, as opposed to being predominantly of donor origin, which is observed in patients who have undergone bone marrow transplantation. Donor-origin PTLDs reportedly follow a more indolent course than host-origin PTLDs. Objective.—To determine the origin of PTLD and its clinical implications in patients who have undergone lung transplantation. Design.—Patients' medical records were reviewed for clinical data. We performed a molecular study to determine the origin of abnormal lymphoid cells in 4 PTLD cases identified from our autopsy files. Each case underwent restriction fragment length polymorphism analysis using polymerase chain reaction–based genotyping for CYP2D6. Epstein-Barr virus (latent membrane protein 1) immunostaining and polymerase chain reaction analysis were performed on PTLD-involved tissues. Results.—Three of 4 PTLD cases were of host origin, and the remaining case was of donor origin. Epstein-Barr virus was detected by immunohistochemical and polymerase chain reaction methods in all PTLD-involved tissues that were examined. There was no apparent difference in clinical manifestations between host-origin and donor-origin PTLD cases in our study. Conclusions.—The PTLDs in our patients who had undergone lung transplantation were Epstein-Barr virus–positive and mostly of host origin, without any notable clinical difference from donor-origin PTLD.

Epstein-Barr Virus Polymerase Chain Reaction and Serology in Pediatric Post-Transplant Lymphoproliferative Disorder: Three-Year Experience

1998 ◽  
Vol 1 (6) ◽  
pp. 480-486 ◽  
Author(s):  
Beverly Barton Rogers ◽  
John Sommerauer ◽  
Albert Quan ◽  
Charles F. Timmons ◽  
D. Brian Dawson ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Response To Therapy ◽  
Chain Reaction ◽  
Post Transplant ◽  
Barr Virus ◽  
Polymerase Chain ◽  
Epstein Barr ◽  
Pcr Test

To assess whether the semiquantitative peripheral blood Epstein-Barr virus (EBV) polymerase chain reaction (PCR) test correlates with post-transplant lymphoproliferative disorder (LPD), we compiled the results of the test done over a 3-year period ending July 1997. Six hundred seventy-six tests were done on 185 patients. Four hundred-thirty tests (63%) were negative, 167 (25%) were weak positive, 67 (10%) were moderate positive, and 12 (2%) were strong positive. Twelve of the patients developed a lymphoproliferative disorder (LPD) during this time. The EBV PCR tests proximate to the diagnosis of LPD in the 12 patients with EBV-positive LPD were 6 strong positive, 5 moderate positive, 1 weak positive. No patient with LPD had a negative result at diagnosis. Stated another way, 6/12 (50%) of strong-positive PCR tests, 5/67 (7%) moderate-positive tests, and 1/167 (.6%) of weak-positive tests correlated with LPD. Serologic evaluation for EBV done on 7 patients at the time of LPD showed low serologic responses in 5 of the 7 patients. The EBV PCR temporally associated with the serology indicated moderate to large viral burdens. In each patient evaluated serially, the EBV PCR test rose before the diagnosis of LPD and fell with treatment for the disorder. In conclusion, the EBV PCR test may be used as an adjunct to the diagnosis of patients with LPD and may be used to monitor response to therapy for the disorder.

scholarly journals Epstein-Barr virus-associated gastric carcinoma in Brazil: comparison between in situ hybridization and polymerase chain reaction detection

2012 ◽  
Vol 43 (1) ◽  
pp. 393-404 ◽  
Author(s):  
Marcos Antonio Pereira de Lima ◽  
Márcia Valéria Pitombeira Ferreira ◽  
Marcos Aurélio Pessoa Barros ◽  
Maria Inês de Moura Campos Pardini ◽  
Adriana Camargo Ferrasi ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
In Situ Hybridization ◽  
Gastric Carcinoma ◽  
Epstein Barr Virus ◽  
Polymerase Chain Reaction Detection ◽  
Chain Reaction ◽  
Barr Virus ◽  
Polymerase Chain ◽  
Epstein Barr

scholarly journals Precision of genotyping of Epstein-Barr virus by polymerase chain reaction using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A virus associated with Hodgkin's disease [published erratum appears in Blood 1993 Oct 1;82(7):2268]

Blood ◽  
1993 ◽  
Vol 81 (12) ◽  
pp. 3372-3381 ◽  
Author(s):  
JC Lin ◽  
SC Lin ◽  
BK De ◽  
WC Chan ◽  
BL Evatt ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Cell Lines ◽  
Epstein Barr Virus ◽  
Point Mutations ◽  
Type A ◽  
Type B ◽  
Chain Reaction ◽  
Barr Virus ◽  
Polymerase Chain ◽  
Epstein Barr

Abstract To precisely determine the genotype of Epstein-Barr virus (EBV) in Hodgkin's disease (HD), we simultaneously analyzed three divergent gene loci (EBNA-2, EBNA-3C, and EBER) that distinguish type A and B viruses. The primers designed to amplify these three gene loci encompass either type-specific deletion sequences (EBNA-2 and EBNA-3C) or type-specific point mutations (EBER) that identify the virus strain based on the sizes of the polymerase chain reaction (PCR)-amplified products or the mobility shifts in single-strand conformation polymorphism analysis. The locations of point mutations were identified by direct sequencing of the PCR-amplified DNA. We analyzed 15 EBV-infected cell lines and found a good correlation between EBNA-2 and EBNA-3C typing results. In contrast, approximately 33% of the cell lines analyzed maintained type A sequences in EBNA-2 and EBNA-3C genes while carrying type B sequences in the EBER region. Data obtained from analysis of cell lines served as a reference for studying HD samples. EBV DNA was detected in about 70% of HD. Among the EBV-positive samples, 56% were associated with type A virus, 13% with type B, and 31% with dual viral sequences. Thus, type A virus is predominant in HD. Based on the histology, the frequencies of EBV positivity were 83%, 71%, and 33% for mixed cellularity, nodular sclerosis, and lymphocyte predominance, respectively. The detection of high frequency of both type A and B sequences in HD may provide a lead in investigating the role of dual viral infection in EBV pathogenesis.

Sign in / Sign up

Export Citation Format

Share Document